Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.
Kleiner DE, Lisker-Melman M, Wahed AS, Bhan AK, Nalesnik MA, Choi EK, Leonard KK, Ghany MG, Chung RT, Di Bisceglie AM; Hepatitis B Research Network. Kleiner DE, et al. Among authors: di bisceglie am. J Gastroenterol Hepatol. 2023 Jun;38(6):989-998. doi: 10.1111/jgh.16167. Epub 2023 Apr 9. J Gastroenterol Hepatol. 2023. PMID: 36890337
Evolution of hepatitis C viral quasispecies after liver transplantation.
Lyra AC, Fan X, Lang DM, Yusim K, Ramrakhiani S, Brunt EM, Korber B, Perelson AS, Di Bisceglie AM. Lyra AC, et al. Among authors: di bisceglie am. Gastroenterology. 2002 Nov;123(5):1485-93. doi: 10.1053/gast.2002.36546. Gastroenterology. 2002. PMID: 12404223
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Shiffman ML, et al. Among authors: di bisceglie am. Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947. doi: 10.1053/j.gastro.2004.01.014. Gastroenterology. 2004. PMID: 15057741 Clinical Trial.
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C; HALT-C Trial Group. Bonkovsky HL, et al. Among authors: di bisceglie am. Gastroenterology. 2006 Nov;131(5):1440-51. doi: 10.1053/j.gastro.2006.08.036. Epub 2006 Aug 18. Gastroenterology. 2006. PMID: 17101320 Clinical Trial.
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group. Everson GT, et al. Among authors: di bisceglie am. Hepatology. 2006 Dec;44(6):1675-84. doi: 10.1002/hep.21440. Hepatology. 2006. PMID: 17133499 Free article. Clinical Trial.
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.
Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, Halt-C Trial Group. Sanyal AJ, et al. Among authors: di bisceglie am. Gastrointest Endosc. 2006 Dec;64(6):855-64. doi: 10.1016/j.gie.2006.03.007. Gastrointest Endosc. 2006. PMID: 17140886 Clinical Trial.
400 results